Investors searching for a "stock price target" for Leidos Holdings, Inc. (LDOS) frequently settle on the $180 area. That is not arbitrary: it sits near the median of current analyst objectives and represents a meaningful recovery from recent levels without requiring the stock to retest its prior peak. Shares have traded in a wide band over the past year, ranging from a low of $98.86 to a high of $205.77, so $180 is a psychologically significant round number roughly halfway between the recent price and the all-time-style peak.
Leidos Holdings is a Reston, Virginia-based technology, engineering, and science company serving U.S. defense, intelligence, civil, and health agencies, alongside commercial customers. Its business is organized across National Security & Digital, Health & Civil, Commercial & International, and Defense Systems segments, with roughly 47,000 employees and annual revenue of about $17 billion.
The stock currently carries a market capitalization near $17.5 billion, a trailing price-to-earnings (P/E) ratio of roughly 13, and a forward P/E near 11. Shares also pay a dividend of $1.72 annually, a yield of about 1.2%. That valuation is comparatively inexpensive for a defense-technology franchise, a key reason some analysts argue the downside is already reflected in the share price.
Several factors support a move toward $180. Leidos raised its full-year 2026 revenue, earnings, and cash-flow guidance after completing its acquisition of Entrust, a cybersecurity and identity-management business, in late March 2026. The deal expands its exposure to digital-identity and cyber markets that align with federal modernization priorities. Management has also cited a near-term contract pipeline measured in the tens of billions of dollars, underpinning a credible growth narrative.
From a technical-analysis perspective, the stock's long-term trend structure remains intact above key support, and any sustained break back above the $160–$165 resistance zone could open a path toward $180. A low forward earnings multiple near 11x also gives the shares room to re-rate if execution improves, since much of the pessimism appears already priced in.
The principal obstacle is the healthcare segment. Analysts have flagged pressure as the Defense Health Agency shifts toward engaging suppliers more directly, as the DHMSM health-records modernization program winds down, and as the Medical Disability Exams contract moves toward recompete. These developments threaten revenue and margins in a business that had previously been a growth engine.
The concerns are reflected in a wave of cautious analyst action. Bank of America downgraded the stock to Neutral and cut its target from $200 to $125, while Jefferies moved to Hold and lowered its target to the $140 area. Goldman Sachs trimmed its objective to $132. The company's book-to-bill ratio also slipped below 1.0x in the first quarter of 2026, a signal that new awards have lagged revenue recognition and will need to improve for the stock to sustain a higher multiple.
The analyst consensus remains broadly constructive but has narrowed. According to S&P Global data, the average 12-month price target is around $157, with a low of $125 and a high of $225. The median target sits closer to $180, which is why that figure features so prominently in the "can Leidos reach $180?" discussion. Notable recent moves include Citi raising its target to $161 with a Buy rating and RBC Capital maintaining an Outperform rating at $170, while more cautious desks cluster in the $132–$145 range. The wide dispersion between $125 and $225 underscores genuine disagreement about whether the healthcare headwinds are temporary or structural.
On the downside, the $125–$135 zone represents the first meaningful support area, followed by the June low near $113 and the 52-week low of $98.86. On the upside, the $160–$165 band is the first major resistance level where analyst targets and prior consolidation converge. A decisive close above that zone would be the clearest technical signal that a run toward $180 and eventually the $205.77 high is underway. Conversely, a failure to hold $125 would likely invalidate the near-term bullish case.
Traders seeking a systematic way to monitor names like Leidos can turn to Tickeron's AI Daily Buy/Sell Signals. The product uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. These signals are designed to help traders surface new opportunities, track existing positions, and identify changing trends more efficiently than manual screening. For investors who want to stay ahead of momentum shifts in a stock as volatile as LDOS, monitoring these AI-generated signals can add a useful, data-driven layer to the decision-making process.
Leidos reaching $180 is realistic but not imminent, and it hinges on the healthcare segment stabilizing and contract awards re-accelerating. The strongest support for the target comes from a cheap valuation, a durable defense and intelligence franchise, raised guidance, and the Entrust acquisition. The primary risks are further healthcare margin erosion, continued sub-1.0x book-to-bill, and the possibility that the recent analyst downgrades prove accurate. Investors should monitor upcoming earnings, book-to-bill trends, and whether the stock can reclaim the $160–$165 resistance zone as the clearest sign that the path to $180 is opening.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, LDOS has been loosely correlated with PSN. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if LDOS jumps, then PSN could also see price increases.
| Ticker / NAME | Correlation To LDOS | 1D Price Change % | ||
|---|---|---|---|---|
| LDOS | 100% | -2.86% | ||
| PSN - LDOS | 52% Loosely correlated | +0.02% | ||
| IT - LDOS | 39% Loosely correlated | -7.42% | ||
| EFOR - LDOS | 30% Poorly correlated | -5.01% | ||
| G - LDOS | 30% Poorly correlated | -5.28% | ||
| EXLS - LDOS | 27% Poorly correlated | -3.03% | ||
More | ||||
| Ticker / NAME | Correlation To LDOS | 1D Price Change % |
|---|---|---|
| LDOS | 100% | -2.86% |
| Technology Services category (397 stocks) | 1% Poorly correlated | -0.87% |